A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

Hamid, Omid; Schmidt, Henrik; Nissan, Aviram; Ridolfi, Laura; Aamdal, Steinar; Hansson, Johan; Guida, Michele; M Hyams, David; Gómez, Henry; Bastholt, Lars; D Chasalow, Scott; Berman, David

doi:10.1186/1479-5876-9-204

Public

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

Shared by NobleBlocks on Nov 28, 2011 • 12:00 AM UTC

Authors:

Omid Hamid

Henrik Schmidt

Aviram Nissan

Abstract

BACKGROUND: Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has demonstrated an improvement in overall survival in two phase III trials of patients with advanced melanoma. The primary objective of the current trial was to prospectively explore candidate bi...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!